Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expanding role of chemotherapy in lung cancer.
Loriot Y, Soria JC, Le Chevalier T. Loriot Y, et al. Ann Oncol. 2006 Sep;17 Suppl 10:x101-7. doi: 10.1093/annonc/mdl246. Ann Oncol. 2006. PMID: 17018709 Free article. Review. No abstract available.
MVP and vinorelbine for malignant pleural mesothelioma.
Mordant P, Loriot Y, Soria JC, Deutsch E. Mordant P, et al. Among authors: loriot y. Lancet. 2008 Aug 23;372(9639):629; author reply 629-30. doi: 10.1016/S0140-6736(08)61273-8. Lancet. 2008. PMID: 18722865 No abstract available.
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. Among authors: loriot y. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.
[Targeting KRAS pathway in NSCLC therapy].
Le Moulec S, Loriot Y, Soria JC. Le Moulec S, et al. Among authors: loriot y. Bull Cancer. 2009 Dec;96 Suppl:S69-74. doi: 10.1684/bdc.2009.0998. Bull Cancer. 2009. PMID: 20034872 French.
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di Palma M, Bossi A, Escudier B, Chauchereau A, Fizazi K. Rajpar S, et al. Among authors: loriot y. Ann Oncol. 2010 Sep;21(9):1864-1869. doi: 10.1093/annonc/mdq037. Epub 2010 Feb 24. Ann Oncol. 2010. PMID: 20181574 Free article.
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
Massard C, Plantade A, Gross-Goupil M, Loriot Y, Besse B, Raynard B, Blot F, Antoun S, Nitenberg G, Escudier B, Fizazi K. Massard C, et al. Among authors: loriot y. Ann Oncol. 2010 Aug;21(8):1585-1588. doi: 10.1093/annonc/mdq021. Epub 2010 Feb 24. Ann Oncol. 2010. PMID: 20181575 Free article.
285 results